GlassScriptPhysician profile
Melanie Raz
NPI 1457972473
$2,473.43
in general payments reported to CMS, 2019-2025
24 companies · $410 in 2025
The $410 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $318 · 2022: $45.89 · 2023: $518 · 2024: $1,182 · 2025: $410.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,110.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,109.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $357.91 | 2024 | Austedo Xr |
| Gilead Sciences, INC. | $246.41 | 2023-2024 | Vemlidy |
| Inspire Medical Systems, INC. | $242.34 | 2024-2025 | Inspire |
| Lilly USA, LLC | $153.36 | 2022-2024 | Omvoh |
| Optinose US, INC. | $148.89 | 2024 | |
| Madrigal Pharmaceuticals | $137.88 | 2025 | Rezdiffra |
| Abbvie INC. | $125.00 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $125.00 | 2024 | Rexulti |
| Regeneron Healthcare Solutions, INC. | $124.99 | 2025 | Dupixent |
| E.R. Squibb & Sons, L.L.C. | $124.46 | 2021 | |
| Tg Therapeutics, INC. | $123.46 | 2023 | |
| Sage Therapeutics, LLC | $115.48 | 2024 | |
| Kyowa Kirin, INC. | $111.73 | 2023 | Nourianz |
| Mylan Specialty L.P. | $109.41 | 2023 | Yupelri |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $91.61 | 2024 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $21.87 | 2023 | Corevalve Evolut R |
| Novo Nordisk INC | $15.98 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.42 | 2023 | Trintellix |
| Kowa Pharmaceuticals America, INC. | $14.96 | 2022 | |
| Merck Sharp & Dohme LLC | $14.70 | 2023 | |
| Glaxosmithkline, LLC. | $14.29 | 2021 | |
| Janssen Pharmaceuticals, INC | $13.06 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.98 | 2021 | |
| Currax Pharmaceuticals LLC | $12.24 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melanie Raz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.